These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 7478613

  • 1. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ.
    Oncogene; 1995 Nov 02; 11(9):1843-51. PubMed ID: 7478613
    [Abstract] [Full Text] [Related]

  • 2. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K.
    Cancer Res; 1995 Jul 01; 55(13):2756-60. PubMed ID: 7796400
    [Abstract] [Full Text] [Related]

  • 3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A, Gaddipati JP, Moul JW, Srivastava S.
    J Urol; 1998 May 01; 159(5):1725-30. PubMed ID: 9554401
    [Abstract] [Full Text] [Related]

  • 4. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T, Mizushima Y, Kashii T, Kobayashi M.
    Anticancer Res; 1998 May 01; 18(3A):1537-42. PubMed ID: 9673367
    [Abstract] [Full Text] [Related]

  • 5. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
    Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T.
    Cancer Res; 1995 Feb 01; 55(3):514-7. PubMed ID: 7834619
    [Abstract] [Full Text] [Related]

  • 6. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA.
    Cancer Res; 1995 Oct 15; 55(20):4531-5. PubMed ID: 7553622
    [Abstract] [Full Text] [Related]

  • 7. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M.
    Cancer; 1996 Jul 15; 78(2):287-93. PubMed ID: 8674005
    [Abstract] [Full Text] [Related]

  • 8. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA.
    Cancer Res; 1996 Mar 01; 56(5):1137-41. PubMed ID: 8640773
    [Abstract] [Full Text] [Related]

  • 9. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.
    Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M.
    Cancer Res; 1995 Apr 01; 55(7):1448-51. PubMed ID: 7882351
    [Abstract] [Full Text] [Related]

  • 10. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR.
    Clin Cancer Res; 1995 Jul 01; 1(7):687-90. PubMed ID: 9816033
    [Abstract] [Full Text] [Related]

  • 11. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H.
    Cancer Res; 1998 Jan 15; 58(2):328-33. PubMed ID: 9443413
    [Abstract] [Full Text] [Related]

  • 12. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R, Shiohara M, Koeffler HP, Fagin JA.
    Cancer; 1998 Nov 15; 83(10):2185-93. PubMed ID: 9827724
    [Abstract] [Full Text] [Related]

  • 13. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK.
    Oncogene; 1995 Mar 16; 10(6):1061-7. PubMed ID: 7700630
    [Abstract] [Full Text] [Related]

  • 14. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK.
    Cancer Res; 1995 May 15; 55(10):2150-7. PubMed ID: 7743516
    [Abstract] [Full Text] [Related]

  • 15. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ, Aldaz CM.
    Cancer Res; 1995 Jul 01; 55(13):2892-5. PubMed ID: 7796417
    [Abstract] [Full Text] [Related]

  • 16. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma.
    Xiao S, Li D, Corson JM, Vijg J, Fletcher JA.
    Cancer Res; 1995 Jul 15; 55(14):2968-71. PubMed ID: 7606711
    [Abstract] [Full Text] [Related]

  • 17. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM, Pearson JV, Hayward NK.
    Genes Chromosomes Cancer; 1996 Feb 15; 15(2):77-88. PubMed ID: 8834170
    [Abstract] [Full Text] [Related]

  • 18. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
    Tenan M, Benedetti S, Finocchiaro G.
    Biochem Biophys Res Commun; 1995 Dec 05; 217(1):195-202. PubMed ID: 8526910
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E.
    Oncogene; 1998 Jan 29; 16(4):497-504. PubMed ID: 9484839
    [Abstract] [Full Text] [Related]

  • 20. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
    Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK.
    Oncogene; 1995 Aug 17; 11(4):663-8. PubMed ID: 7651729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.